Match Document Document Title
9040055 Conjugation of streptococcal capsular saccharides  
Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the...
9040057 Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases  
A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of...
9034345 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis  
The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis...
9023363 A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines  
The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1...
9017692 Antimicrobial agent, bacterial strain, biosynthesis, and methods of use  
Provided herein is a biologically pure culture of Paenibacillus thiaminolyticus, identified as OSY-SE, as well as an antimicrobial agent isolated and/or purified from the culture having any one of...
9018360 Modified biotin-binding protein  
The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and...
RE45467 Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications  
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same...
8992936 Altered OspA of Borrelia burgdorferi  
Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA...
8993302 Mutants of Francisella tularensis and uses thereof  
The present invention relates to a mutant Francisella tularensis strain comprising an inactivated clpB gene and compositions comprising such mutant. Methods of producing the mutant are also...
8992935 Means of controlling infection persistence of Helicobacter pylori  
The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified...
8986704 Mutant fragments of OspA and methods and uses relating thereto  
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use...
8986708 Combinations of gene deletions for live attenuated Shigella vaccine strains  
Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2...
8986710 Neisseria meningitidis compositions and methods thereof  
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an...
8980274 Ehrlichia canis DIVA (differentiate infected from vaccinated animals)  
The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also...
8980286 Multiple variants of meningococcal protein NBM1870  
Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it...
8974798 Anti-bacterial vaccine compositions with a mutated yleA gene  
Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision...
8968748 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis  
The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis...
8961989 Methods for producing an immune response to tuberculosis  
Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional...
8961990 Vaccine and methods to reduce campylobacter infection  
Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first...
8956621 Compositions and methods for treatment of cervical dysplasia  
The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a...
8951531 Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides  
This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against...
8945589 Immunogenic compositions for Streptococcus agalactiae  
This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a...
8945580 Yersinia pestis antigens, vaccine compositions, and related methods  
The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis. The present invention provides pharmaceutical compositions of such antigens and/or...
8936792 Pseudomonas exotoxin a with reduced immunogenicity  
The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.
8932600 Modified tuberculosis antigens  
Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
8932609 Flagellin related polypeptides and uses thereof  
The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
8926989 Compositions and methods for screening for Lyme disease  
The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.
8926990 Treatment and diagnosis of inflammatory disorders and HIV  
This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
8920809 Chimera comprising bacterial cytotoxin and methods of using the same  
This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the...
8916166 Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease  
The invention is directed to vaccine compositions and methods based on P. gingivalis proteins identified to be regulated by haem availability that can be used in the prevention and treatment of...
8911743 Haemophilus parasuis polypeptides and methods of use  
The present invention provides isolated polypeptides having oligopeptide permease activity and an amino acid sequence that has at least 80% identity with a Haemophilus parasuis OppA polypeptide....
8911748 Cholera toxin chimera and its use as a staph vaccine  
The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of...
8911745 Immunology treatment for biofilms  
The invention provides a composition for use in raising an immune response to P. gingivalis in a subject, the composition comprising an amount effective to raise an immune response of at least one...
8907060 Mutated Pseudomonas exotoxins with reduced antigenicity  
The invention provides mutated Pseudomonas exotoxins (PE) that have reduced immunogenicity compared to PEs containing the native sequence. The PEs of the invention have one or more individual...
8900597 Compositions relating to a mutant Clostridium difficile toxin and methods thereof  
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a...
8900598 Multicomponent or monocomponent vaccine to be used against Chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure  
A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine...
8895019 Biofilm treatment  
The invention provides a method of preventing, inhibiting or reducing a P. gingivalis biofilm in a subject comprising administering to the subject a pharmaceutical composition comprising an...
8895006 Ricin ribosome binding protein compositions and methods of use thereof  
Compositions and methods for treatment of toxin poisoning are disclosed.
8895257 Proteins used for the diagnosis of lyme borreliosis  
Chimera proteins including: (i) at least one sequence of a VlsE protein of a Borrelia species selected from B. garinii, B. burgdorferi sensu stricto and B. afzelii, and (ii) at least one sequence...
8895030 Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system  
The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their...
8889142 Chlamydia trachomatis antigens for vaccine and diagnostic use  
The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the...
8889128 Use of the endoglycosidase endos for treating immunoglobulin G mediated diseases  
The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition...
8889150 Bacterial vaccine components from Staphylococcus aureus and uses thereof  
Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from...
8883172 Chemically modified peptides with improved immunogenicity  
The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides...
8871213 Prevention, treatment and diagnosis of P. gingivalis infection  
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.
8871215 Flagellin related polypeptides and uses thereof  
The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.
8871214 Detoxified Escherichia coli immunogens  
Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein....
8858957 GAS57 mutant antigens and GAS57 antibodies  
The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The...
8846342 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells  
The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising...
8840901 YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions  
The present invention relates to the use of Yersinia outer protein M (YopM), a YopM fragment, or a YopM variant, which is capable of autopenetrating the cell membrane and of integrating into the...